BackSinovac Biotech, Overview

Sinovac Biotech, Long Term Debt

Latest long-term debt for SVA: $270M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$274.12M

Peer trimmed avg / median

Loading

Sinovac Biotech, Long Term Debt History

Loading

Sinovac Biotech, vs. peers: Long Term Debt Comparison

Loading

Sinovac Biotech, Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Sinovac Biotech, (SVA) FAQ

As of the most recent data (December 2025), SVA shows a long-term debt of $270M. Scroll down for historical charts and peer comparison views.

Tracking SVA's long-term debt over time shows whether Sinovac Biotech, is scaling, shrinking, or reshaping that part of the business. The current reading is $270M Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Sinovac Biotech,'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $270M) with ownership activity and broader fundamentals.

Sinovac Biotech,'s long-term debt is $270M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.